000286085 001__ 286085
000286085 005__ 20240229155120.0
000286085 0247_ $$2doi$$a10.3390/cancers15235514
000286085 0247_ $$2pmid$$apmid:38067218
000286085 0247_ $$2pmc$$apmc:PMC10705117
000286085 0247_ $$2altmetric$$aaltmetric:157367586
000286085 037__ $$aDKFZ-2023-02661
000286085 041__ $$aEnglish
000286085 082__ $$a610
000286085 1001_ $$aEtemad, Mani$$b0
000286085 245__ $$aC-Type Lectin-like Receptor 2 Expression Is Decreased upon Platelet Activation and Is Lower in Most Tumor Entities Compared to Healthy Controls.
000286085 260__ $$aBasel$$bMDPI$$c2023
000286085 3367_ $$2DRIVER$$aarticle
000286085 3367_ $$2DataCite$$aOutput Types/Journal article
000286085 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1702378100_9556
000286085 3367_ $$2BibTeX$$aARTICLE
000286085 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000286085 3367_ $$00$$2EndNote$$aJournal Article
000286085 520__ $$aThe C-type lectin-like receptor 2 (CLEC-2) is expressed on platelets and mediates binding to podoplanin (PDPN) on various cell types. The binding to circulating tumor cells (CTCs) leads to platelet activation and promotes metastatic spread. An increased level of soluble CLEC-2 (sCLEC-2), presumably released from activated platelets, was shown in patients with thromboinflammatory and malignant disease. However, the functional role of sCLEC-2 and the mechanism of sCLEC-2 release are not known. In this study, we focused on the effect of platelet activation on CLEC-2 expression and the sCLEC-2 plasma level in patients with cancer. First, citrated blood from healthy volunteer donors (n = 20) was used to measure the effect of platelet stimulation by classical agonists and PDPN on aggregation, CLEC-2 expression on platelets with flow cytometry, sCLEC-2 release to the plasma with ELISA and total CLEC-2 expression with Western blot analysis. Second, sCLEC-2 was determined in plasma samples from healthy donors (285) and patients with colorectal carcinoma (CRC; 194), melanoma (160), breast cancer (BC; 99) or glioblastoma (49). PDPN caused a significant increase in the aggregation response induced by classical agonists. ADP or PDPN stimulation of platelets caused a significant decrease in CLEC-2 on platelets and sCLEC-2 in the plasma, whereas total CLEC-2 in platelet lysates remained the same. Thus, the increased plasma level of sCLEC-2 is not a suitable biomarker of platelet activation. In patients with CRC (median 0.9 ng/mL), melanoma (0.9 ng/mL) or BC (0.7 ng/mL), we found significantly lower sCLEC-2 levels (p < 0.0001), whereas patients with glioblastoma displayed higher levels (2.6 ng/mL; p = 0.0233) compared to healthy controls (2.1 ng/mL). The low sCLEC-2 plasma level observed in most of the tumor entities of our study presumably results from the internalization of sCLEC-2 by activated platelets or binding of sCLEC-2 to CTCs.
000286085 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000286085 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000286085 650_7 $$2Other$$acancer thrombosis
000286085 650_7 $$2Other$$aplatelet function
000286085 650_7 $$2Other$$apodoplanin
000286085 650_7 $$2Other$$asoluble CLEC-2
000286085 7001_ $$aChristodoulou, Foteini$$b1
000286085 7001_ $$aUhlig, Stefanie$$b2
000286085 7001_ $$aHassel, Jessica C$$b3
000286085 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b4$$udkfz
000286085 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b5$$udkfz
000286085 7001_ $$00000-0001-7641-059X$$aUlrich, Cornelia M$$b6
000286085 7001_ $$00000-0003-2621-0703$$aBieback, Karen$$b7
000286085 7001_ $$aKlüter, Harald$$b8
000286085 7001_ $$aBugert, Peter$$b9
000286085 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers15235514$$gVol. 15, no. 23, p. 5514 -$$n23$$p5514$$tCancers$$v15$$x2072-6694$$y2023
000286085 909CO $$ooai:inrepo02.dkfz.de:286085$$pVDB
000286085 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000286085 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000286085 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000286085 9141_ $$y2023
000286085 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2022$$d2023-10-26
000286085 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000286085 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000286085 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000286085 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-31T16:07:06Z
000286085 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-31T16:07:06Z
000286085 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-31T16:07:06Z
000286085 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-07-31T16:07:06Z
000286085 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000286085 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000286085 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000286085 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000286085 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-26
000286085 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000286085 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-26
000286085 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-26
000286085 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2022$$d2023-10-26
000286085 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-26
000286085 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-26
000286085 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000286085 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000286085 980__ $$ajournal
000286085 980__ $$aVDB
000286085 980__ $$aI:(DE-He78)C120-20160331
000286085 980__ $$aI:(DE-He78)C070-20160331
000286085 980__ $$aUNRESTRICTED